BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18215514)

  • 1. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease.
    Bergeron C; Thiesse P; Rey A; Orbach D; Boutard P; Thomas C; Schmitt C; Scopinaro MJ; Bernard F; Stevens M; Oberlin O
    Eur J Cancer; 2008 Feb; 44(3):427-31. PubMed ID: 18215514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma.
    Chisholm JC; Machin D; McDowell H; McHugh K; Ellershaw C; Jenney M; Foot AB;
    Eur J Cancer; 2007 Nov; 43(17):2537-44. PubMed ID: 17962012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
    Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
    J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
    Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
    Douglas JG; Arndt CA; Hawkins DS
    Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP;
    J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
    Klingebiel T; Boos J; Beske F; Hallmen E; Int-Veen C; Dantonello T; Treuner J; Gadner H; Marky I; Kazanowska B; Koscielniak E
    Pediatr Blood Cancer; 2008 Apr; 50(4):739-45. PubMed ID: 18286501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Sandler E; Lyden E; Ruymann F; Maurer H; Wharam M; Parham D; Link M; Crist W
    Med Pediatr Oncol; 2001 Nov; 37(5):442-8. PubMed ID: 11745872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoma of the prostate: a single institutional review.
    Janet NL; May AW; Akins RS
    Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma.
    Etcubanas E; Horowitz M; Vogel R
    Cancer Treat Rep; 1985 Sep; 69(9):999-1000. PubMed ID: 4028041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Lashkari A; Chow WA; Valdes F; Leong L; Phan V; Twardowski P; Kapoor N; Molina A; Al-Kadhimi Z; Frankel P; Somlo G
    Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
    Pappo AS; Lyden E; Breneman J; Wiener E; Teot L; Meza J; Crist W; Vietti T
    J Clin Oncol; 2001 Jan; 19(1):213-9. PubMed ID: 11134215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.